Abstracts tagged "rheumatoid arthritis (RA) and rituximab"

Abstract Number: 1280 • 2012 ACR/ARHP Annual Meeting
Sustained Efficacy Responses and a Consistent Safety Profile with Rituximab Repeat Treatment Over 5 Years in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumour Necrosis Factor Inhibitors
Edward Keystone¹, Stanley B. Cohen², Paul Emery³, Joel M. Kremer⁴, Maxime R. Dougados⁵, James E. Loveless⁶, Carol Chung⁷, Pamela Wong⁷, Patrica B. Lehane⁸ and Helen Tyrrell⁸, ¹The Rebecca MacDonald Centre for Arthritis and Autoimmunity, Mount Sinai Hospital, Toronto, ON, Canada, ²Metroplex Clinical Research Center, Dallas, TX, ³Division of Rheumatic & Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ⁴Center for Rheumatology, Albany Medical College, Albany, NY, ⁵Hopital Cochin, René Descartes University, Paris, France, ⁶St Luke's Rheumatology, Boise, ID, ⁷Genentech, Inc., South San Francisco, CA, ⁸Roche Products Limited, Welwyn Garden City, United Kingdom
Background/Purpose: In the REFLEX study conducted in anti-TNF inadequate responder (TNF-IR) patients with RA, a single course of rituximab (RTX) in combination with methotrexate (MTX)…
Abstract Number: 1273 • 2012 ACR/ARHP Annual Meeting
Can Response Duration After the First Rituximab Treatment Be Used in Timing of Rituximab Retreatment?
Noortje van Herwaarden¹, Aatke van der Maas¹, Tim L. Jansen², Ellen Dutmer³, Andre Hartkamp⁴, Piet L.C.M. van Riel⁵, Wietske Kievit⁵, Bart J.F. van den Bemt⁶ and Alfons A. den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Rheumatology, Radboud UMC, Nijmegen, Netherlands, ³Rheumatology, Gelderse Vallei Hospital, Ede, Netherlands, ⁴Reumatology, Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands, ⁵Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁶Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: The optimal retreatment strategy for rituximab is not clear1. Different strategies are being used in clinical practice, including: on demand retreatment when disease activity…
Abstract Number: 1004 • 2012 ACR/ARHP Annual Meeting
A Unique Single Nucleotide Polymorphism in the 3’ UTR of the MED29 Gene On Chromosome 19 Is Associated with the Clinical Outcome of Different Biologic Response Modifiers
Susanne Drynda¹, David Leesch², Marietta Gloetzner² and Joern Kekow², ¹Clinic of Rheumatology, Univ of Magdeburg, Clinic of Rheumatology, Vogelsang-Gommern, Germany, ²Clinic of Rheumatology, Univ of Magdeburg, Vogelsang-Gommern, Germany
Background/Purpose: Due to the wide range of highly specific and effective biologic response modifiers that are available today for the treatment of RA it has…
Abstract Number: 482 • 2012 ACR/ARHP Annual Meeting
B-Lymphocyte Count Is Not Associated with an Increased Risk of Infection in Patients Treated with Rituximab for Auto-Immune Diseases
Ilias Lazarou¹, Axel Finckh², Lara Fischer³, Camillo Ribi³, Joerg Seebach³ and Pierre A. Guerne², ¹University Hospitals of Geneva, Geneva, Switzerland, ²Rheumatology, University Hospitals of Geneva, Geneva, Switzerland, ³Immunology, University Hospitals of Geneva, Geneva, Switzerland
Background/Purpose: B-Lymphocyte (B-Ly) depletion therapy with the monoclonal anti-CD20 antibody rituximab (RTX) is widely used in a variety of autoimmune (AI) diseases. The risk of…
Abstract Number: 2543 • 2012 ACR/ARHP Annual Meeting
Hospitalized Bacterial Infections Among U.S. Veterans with Rheumatoid Arthritis Initiating TNF Antagonist and Newer Biologic Agents
Jeffrey R. Curtis¹, Shuo Yang², Nivedita M. Patkar³, Lang Chen⁴, Jasvinder A. Singh⁵, Grant W. Cannon⁶, Ted R. Mikuls⁷, Elizabeth S. Delzell⁸, Kenneth G. Saag⁹, Monika M. Safford¹⁰, Scott DuVall¹¹, Kimberly Alexander¹², Pavel Napalkov¹², Aaron Kamauu¹³ and John Baddley¹⁴, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Immunology/Rheumatology, Univ of Alabama-Birmingham, Birmingham, AL, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Department of Medicine, University of Alabama, Tuscaloosa, AL, ⁶Division of Rheumatology, George E. Wahlen VA Medical Center, Salt Lake City, UT, ⁷Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁸Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁹Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ¹⁰Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹¹VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ¹²Epidemiology, Genentech, Inc., South San Francisco, CA, ¹³Anolinx, Bountiful, UT, ¹⁴Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Risks of hospitalized infections for newer biologic agents have not been well characterized compared to risks for anti-TNF therapy. Purpose: To compare the risk…
Abstract Number: 2168 • 2012 ACR/ARHP Annual Meeting
Tolerance and Efficacy of Rituximab in Elderly Patients with Rheumatoid Arthritis Enrolled in the French Society of Rheumatology Air Registry
Sarah Payet¹, Jacques-Eric Gottenberg², Xavier Mariette³, Philippe Ravaud⁴, Elodie Perrodeau⁵, Thomas Bardin⁶, Patrice Cacoub⁷, Alain G. Cantagrel⁸, Bernard Combe⁹, Maxime Dougados¹⁰, Rene-Marc Flipo¹¹, Bertrand Godeau¹², Loic Guillevin¹³, Xavier X. Le Loet¹⁴, Eric Hachulla¹⁵, Thierry Schaeverbeke¹⁶, Jean Sibilia¹⁷, Isabelle Pane¹⁸, Gabriel Baron¹⁹ and Martin Soubrier²⁰, ¹Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, ²Rheumatology, Strasbourg University Hospital, Strasbourg, France, ³Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ⁴Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ⁵Epidemiologist, Paris, France, ⁶Rheumatology, Hôpital Lariboisière, Paris, France, ⁷Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁸Dept of Rheumatology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France, ⁹Rheumatology, Hopital Lapeyronie, Montpellier, France, ¹⁰Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ¹¹Rheumatology, Hopital R Salengro CHRU, Lille, France, ¹²Internal Medicine, University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, ¹³Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, ¹⁴Rheumatology Department, CHU de ROUEN, Rouen, France, ¹⁵Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹⁶Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ¹⁷Université de Strasbourg, EA4438 Laboratoire Physiopathologie des Arthrites, Illkirch-Strasbourg, France, ¹⁸Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, ¹⁹Hotel Dieu University Hospital Paris, Epidemiology, Paris, France, ²⁰Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France
Background/Purpose: This study aimed to compare the efficacy and the safety of Rituximab (RTX)in elderly (aged ≥ 65years) and younger patients (aged 18-64 years) with…
Abstract Number: 1758 • 2012 ACR/ARHP Annual Meeting
Serum BAFF Levels and Relationship with BAFF Binding Receptors in Patients with Rheumatoid Arthritis Relapsing After B Cell Depletion Therapy
Elena Becerra¹, Inmaculada de la Torre², Maria J. Leandro³ and Geraldine Cambridge³, ¹Rheumatology, University College London, London, United Kingdom, ²Rheumatology, Gregorio Marañón Hospital, Madrid, Spain, ³Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom
Background/Purpose: B-cell-activating-factor (BAFF) coordinates differentiation of B cells into immunoglobulin secreting cells (ISC) by binding to 3 different receptors (BBRs), namely BAFF-R, transmembrane activator and…
Abstract Number: 1753 • 2012 ACR/ARHP Annual Meeting
A Rheumatoid Factor Paradox: Inhibition of Rituximab-Induced Complement Dependent Cytotoxicity of B Cells
Jonathan D. Jones¹, Irene Shyu², Marianna M. Newkirk³ and William F. C. Rigby², ¹Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, ²Rheumatology, Dartmouth-Hitchcock Med Ctr, Lebanon, NH, ³Medicine, McGill University Health Centr, Montreal, QC, Canada
Background/Purpose: Rheumatoid factor (RF) is an autoantibody directed against the Fc portion of IgG antibodies. It is found in ~80% of patients with rheumatoid…
Abstract Number: 1757 • 2012 ACR/ARHP Annual Meeting
B Cell Activating Factor Receptor Expression After Rituximab: Comparison of Patients with Rheumatoid Arthritis and Thrombotic Thrombocytopenic Purpura
Elena Becerra¹, Maria J. Leandro¹, Edward O. Heelas², John P. Westwood², Inmaculada de la Torre³, Marie A. Scully² and Geraldine Cambridge¹, ¹Rheumatology, Rheumatology, University College London, London, United Kingdom, ²Hematology, Hematology, University College London, London, United Kingdom, ³Rheumatology, Rheumatology, Gregorio Marañón Hospital, Madrid, Spain
Background/Purpose: B cell depletion therapy based on rituximab (RTX) is an effective therapy for Rheumatoid Arthritis (RA) and for Thrombotic Thrombocytopenic Purpura (TTP). Serum B…
Abstract Number: 1699 • 2012 ACR/ARHP Annual Meeting
Neutropenia After Rituximab in Rheumatoid Arthritis and Other Autoimmune Diseases Is a Rare Events : Date From the Autoimmunity and Rituximab Registry
Jean Hugues Salmon¹, Patrice Cacoub², Bernard G. Combe³, Jean Sibilia⁴, Beatrice Pallot Prades⁵, Olivier Fain⁶, Alain G. Cantagrel⁷, Maxime Dougados⁸, Olivier Meyer⁹, Philippe Carli¹⁰, Edouard Pertuiset¹¹, Isabelle Pane¹², Philippe Ravaud¹³, Xavier Mariette¹⁴ and Jacques-Eric Gottenberg¹⁵, ¹Rheumatology, Reims, France, ²Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ³Rhumatologie, Hopital Lapeyronie, Montpellier, France, ⁴Rheumatology, CHU Hautepierre, Strasbourg, France, ⁵Rheumatology department, Saint Etienne university hospital, Saint Etienne, France, ⁶Internal Medicine, Jean Verdier Hospital, Bondy, France, ⁷Rheumatology, Place du Docteur Baylac, Toulouse, France, ⁸Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁹Rheumatology, Hopital Bichat, Paris, France, ¹⁰HIA sainte Anne, Toulon, France, ¹¹Rheumatology, Ch Rene Dubos, Pontoise, France, ¹²Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, ¹³Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ¹⁴Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ¹⁵Rheumatology, Strasbourg University Hospital, Strasbourg, France
Background/Purpose: Limited data are available regarding the proportion and severity of late onset neutropenia after RTX in large and unselected populations of patients with various…
Abstract Number: 1305 • 2012 ACR/ARHP Annual Meeting
Three-Year Follow-up of Rituximab in Rheumatoid Arthritis: Results From the Belgian MIRA (MabThera in Rheumatoid Arthritis) Registry
Filip De Keyser¹, Patrick Durez², Rene Westhovens³, marie-Joelle Kaiser⁴ and Ilse Hoffman⁵, ¹Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ²Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium, ³Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ⁴Rheumatology, Dept Rheumatology, University Hospital Liege, Belgium, Belgium, ⁵Rheumatology, Dept Rheumatology, GZA St-Augustinus Hospital Antwerp, Belgium, Wilrijk, Belgium
Background/Purpose: The MIRA registry was set up to collect safety, efficacy and (re)treatment practice data for Belgian RA patients treated with rituximab. Methods: All rheumatologists…
Abstract Number: 1308 • 2012 ACR/ARHP Annual Meeting
Opportunistic Infections in Patients with Rheumatoid Arthritis Treated with Rituximab : Data From the Autoimmunity and Rituximab Registry
Jacques-Eric Gottenberg¹, Philippe Ravaud², Thomas Bardin³, Patrice Cacoub⁴, Alain G. Cantagrel⁵, Bernard Combe⁶, Maxime Dougados⁷, Rene-Marc Flipo⁸, Bertrand Godeau⁹, Loic Guillevin¹⁰, Xavier X. Le Loet¹¹, Eric Hachulla¹², Thierry Schaeverbeke¹³, Jean Sibilia¹⁴, Isabelle Pane¹⁵, Gabriel Baron¹⁶ and Xavier Mariette¹⁷, ¹Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ³Rheumatology, Hôpital Lariboisière, Paris, France, ⁴Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁵Rheumatology, Place du Docteur Baylac, Toulouse, France, ⁶Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁷Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ⁸Rheumatology, Hopital R Salengro CHRU, Lille, France, ⁹Internal Medicine, University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, ¹⁰Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ¹¹Rheumatology Department, CHU de ROUEN, Rouen, France, ¹²Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹³Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ¹⁴Rheumatology, CHU Hautepierre, Strasbourg, France, ¹⁵Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, ¹⁶Epidemiology, Strasbourg, France, ¹⁷Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France
Background/Purpose: Therapy with biological agents may be associated with opportunistic infections (OIs). Data on the occurrence of OIs in patients with RA treated with rituximab…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].